55558-81-1

Upstream product

• 39757-29-4 methyl 2,4-dioxo-4-p-tolylbutanoate 
• 5814-37-9 ethyl-4-(4-methylphenyl)-2,4-dioxobutyrate 
• 122-00-9 para-methylacetophenone 
• 95-92-1 oxalic acid diethyl ester 
• 108-88-3 toluene 

Downstream Products

• 134949-92-1 (E)-5,5'-di-p-tolyl-[3,3']bifurylidene-2,2'-dione 
• 40598-79-6 2-(p-tolyl)furo[2,3-b]quinoxaline 
• 64393-76-6 2-(2-oxo-2-p-tolyl-ethylidene)-4H-benzo[1,4]thiazin-3-one 
• 55991-68-9 5-(p-tolyl)-2,3-dihydro-2,3-furandione 
• 103311-11-1 2-(2-Oxo-2-p-tolyl-ethyl)-4H-benzo[4,5]imidazo[1,2-b][1,2,4]triazin-3-one 
• 103311-14-4 2,4-Dioxo-4-p-tolyl-butyric acid; compound with benzoimidazole-1,2-diamine 
• 139266-62-9 (2Z,4Z)-1,6-di(4-methylphenyl)-3,4-dihydroxy-2,4-hexadiene-1,6-dione 
• 139266-58-3 (2Z,4Z)-1-(4-Bromo-phenyl)-3,4-dihydroxy-6-p-tolyl-hexa-2,4-diene-1,6-dione 
• 149281-70-9 2-[2-(4-Bromo-phenyl)-2-oxo-eth-(Z)-ylidene]-5-p-tolyl-furan-3-one 

Relevant academic research and scientific papers

Non-peptide-based new class of platelet aggregation inhibitors: Design, synthesis, bioevaluation, SAR, and in silico studies

A series of 2-oxo-2-phenylethylidene linked 2-oxo-benzo[1,4]oxazine analogues 17a–x and 18a–o, incorporated with a variety of electron-withdrawing as well as electron-donating groups at ring A and ring C, were synthesized under greener conditions in excel

Furan-2,3-diones as masked dipoles: synthesis of isotetronic acids and mechanistic considerations

The formal dipolar behaviour of furan-2,3-diones is illustrated by their reaction with ethyl glyoxylate under Lewis basic activation uniquely, giving access to isotetronic derivatives. The Janus-type nature of the activated species, both nucleophilic and

5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII

Inhibitory activity of a congeneric set of 23 phenyl-substituted 5-phenyl-pyrazole-3-carboxylic acids toward human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms I, II, IX and XII was evaluated by a stopped-flow CO2 hydrase assay. These compounds exerted a clear, selective inhibition of hCA IX and XII over hCAI and II, with Ki in two to one digit micromolar concentrations (4-50 μM). Derivatives bearing bulkier substituents in para-position of the phenyl ring inhibited hCA XII at one-digit micromolar concentrations, while derivatives having alkyl substituents in both ortho- and meta-positions inhibited hCA IX with Kis ranging between 5 and 25 μM. Results of docking experiments offered a rational explanation on the selectivity of these compounds toward CA IX and XII, as well as on the substitution patterns leading to best CA IX or CA XII inhibitors. By examining the active sites of these four isoforms with GRID generated molecular-interaction fields, striking differences between hCA XII and the other three isoforms were observed. The field of hydrophobic probe (DRY) appeared significantly different in CA XII active site, comparing to other three isoforms studied. To the best of our knowledge such an observation was not reported in literature so far. Considering the selectivity of these carboxylates towards membrane-associated over cytosolic CA isoforms, the title compounds could be useful for the development of isoform-specific non-sulfonamide CA inhibitors.

Discovery of α,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase

α,γ-Diketo acids (DKA) were discovered from screening as selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. The diketo acid moiety proved essential for activity, while substitution on the γ position was necessary for selectivity and potency. Optimization led to the identification of a DKA inhibitor of NS5b polymerase with IC50 = 45 nM, one of the most potent HCV NS5b polymerase inhibitors reported.